FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221031853> ?p ?o ?g. }

• W4221031853 abstract "Previous studies have found tacrolimus to be a favorable drug for treating different types of myasthenia gravis (MG), but few have focused on very-late-onset MG (VLOMG). This study evaluated the efficacy and safety of tacrolimus for VLOMG therapy.This was a retrospective single-center cohort study of 70 patients with VLOMG (onset ≥65 years) who visited Peking University First Hospital in 2019. Participants were divided into the tacrolimus (Tac) group and the control group based on tacrolimus usage. We further divided the Tac group into patients treated without corticosteroids and with corticosteroids. Sociodemographic features, clinical profiles, and outcomes were compared between different therapies and further analyzed by multivariate regression. Details of tacrolimus treatment, comorbidities, and adverse drug reactions (ADRs) were described.Among 70 patients, the median (interquartile range) age at onset was 71 (68-77) years, and the follow-up duration was 27 (27-29) months. Most patients were types I (28%) and III (40%) according to the MG Foundation of America (MGFA) classification. In the Tac group, tacrolimus treatment was maintained for 36 (27-38) months. The dosage at the final evaluation was 1.0 (1.0-1.75) mg/day, and the last blood concentration test was 4.25 (2.85-5.7) ng/ml. A total of 43% reached remission, and 37% improved based on MGFA postintervention status (MGFA-PIS). For the 9 patients, newly diagnosed at enrollment within this group, MG activities of daily living (MG-ADL) decreased significantly from 3 (2-5) to 2 (1-2) (p = 0.041). Regarding the 13 patients, coadministering Wuzhi capsules the tacrolimus concentration increased from 2.75 (1.4-3.8) ng/ml to 5.95 (5.1-7.0) ng/ml (p = 0.012). No significant differences in outcomes were observed between tacrolimus treatment without and with corticosteroids or between the Tac group and the control group. A total of 93% had at least one comorbidity. ADRs related to tacrolimus emerged in 25% (9/36) of patients, most of which were not serious and reversible.Tacrolimus is effective and safe in treating VLOMG. Tacrolimus monotherapy without corticosteroids can be used as an initial and maintenance treatment for VLOMG. Wuzhi capsules work well in elevating tacrolimus concentrations in this population." @default.
• W4221031853 created "2022-04-03" @default.
• W4221031853 creator A5006612263 @default.
• W4221031853 creator A5017908547 @default.
• W4221031853 creator A5034579880 @default.
• W4221031853 creator A5035286503 @default.
• W4221031853 creator A5052394997 @default.
• W4221031853 creator A5057342639 @default.
• W4221031853 creator A5067763780 @default.
• W4221031853 creator A5074934997 @default.
• W4221031853 creator A5077554698 @default.
• W4221031853 creator A5081489339 @default.
• W4221031853 creator A5090010759 @default.
• W4221031853 date "2022-03-30" @default.
• W4221031853 modified "2023-09-26" @default.
• W4221031853 title "Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis" @default.
• W4221031853 cites W139009177 @default.
• W4221031853 cites W1897013744 @default.
• W4221031853 cites W1952164132 @default.
• W4221031853 cites W1971890669 @default.
• W4221031853 cites W1980271590 @default.
• W4221031853 cites W2058548181 @default.
• W4221031853 cites W2080004493 @default.
• W4221031853 cites W2093381574 @default.
• W4221031853 cites W2119417201 @default.
• W4221031853 cites W2129124562 @default.
• W4221031853 cites W2138746931 @default.
• W4221031853 cites W2139573761 @default.
• W4221031853 cites W2164051173 @default.
• W4221031853 cites W2473388648 @default.
• W4221031853 cites W2554073739 @default.
• W4221031853 cites W2567758517 @default.
• W4221031853 cites W2587471491 @default.
• W4221031853 cites W2607192280 @default.
• W4221031853 cites W2623745768 @default.
• W4221031853 cites W2736536338 @default.
• W4221031853 cites W2789526819 @default.
• W4221031853 cites W2886019789 @default.
• W4221031853 cites W2896586515 @default.
• W4221031853 cites W2905118355 @default.
• W4221031853 cites W2937473679 @default.
• W4221031853 cites W2954223196 @default.
• W4221031853 cites W2997563714 @default.
• W4221031853 cites W3005198668 @default.
• W4221031853 cites W3008214101 @default.
• W4221031853 cites W3010660498 @default.
• W4221031853 cites W3047340905 @default.
• W4221031853 cites W3093749281 @default.
• W4221031853 cites W3097591800 @default.
• W4221031853 cites W3108879275 @default.
• W4221031853 cites W3143903046 @default.
• W4221031853 cites W3177595832 @default.
• W4221031853 cites W3177737735 @default.
• W4221031853 cites W3183443026 @default.
• W4221031853 cites W3216913271 @default.
• W4221031853 cites W4211188347 @default.
• W4221031853 doi "https://doi.org/10.3389/fneur.2022.843523" @default.
• W4221031853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35432159" @default.
• W4221031853 hasPublicationYear "2022" @default.
• W4221031853 type Work @default.
• W4221031853 citedByCount "3" @default.
• W4221031853 countsByYear W42210318532022 @default.
• W4221031853 countsByYear W42210318532023 @default.
• W4221031853 crossrefType "journal-article" @default.
• W4221031853 hasAuthorship W4221031853A5006612263 @default.
• W4221031853 hasAuthorship W4221031853A5017908547 @default.
• W4221031853 hasAuthorship W4221031853A5034579880 @default.
• W4221031853 hasAuthorship W4221031853A5035286503 @default.
• W4221031853 hasAuthorship W4221031853A5052394997 @default.
• W4221031853 hasAuthorship W4221031853A5057342639 @default.
• W4221031853 hasAuthorship W4221031853A5067763780 @default.
• W4221031853 hasAuthorship W4221031853A5074934997 @default.
• W4221031853 hasAuthorship W4221031853A5077554698 @default.
• W4221031853 hasAuthorship W4221031853A5081489339 @default.
• W4221031853 hasAuthorship W4221031853A5090010759 @default.
• W4221031853 hasBestOaLocation W42210318531 @default.
• W4221031853 hasConcept C119060515 @default.
• W4221031853 hasConcept C126322002 @default.
• W4221031853 hasConcept C167135981 @default.
• W4221031853 hasConcept C197934379 @default.
• W4221031853 hasConcept C2778105408 @default.
• W4221031853 hasConcept C2909675724 @default.
• W4221031853 hasConcept C2911091166 @default.
• W4221031853 hasConcept C71924100 @default.
• W4221031853 hasConcept C72563966 @default.
• W4221031853 hasConceptScore W4221031853C119060515 @default.
• W4221031853 hasConceptScore W4221031853C126322002 @default.
• W4221031853 hasConceptScore W4221031853C167135981 @default.
• W4221031853 hasConceptScore W4221031853C197934379 @default.
• W4221031853 hasConceptScore W4221031853C2778105408 @default.
• W4221031853 hasConceptScore W4221031853C2909675724 @default.
• W4221031853 hasConceptScore W4221031853C2911091166 @default.
• W4221031853 hasConceptScore W4221031853C71924100 @default.
• W4221031853 hasConceptScore W4221031853C72563966 @default.
• W4221031853 hasFunder F4320317365 @default.
• W4221031853 hasLocation W42210318531 @default.
• W4221031853 hasLocation W42210318532 @default.
• W4221031853 hasLocation W42210318533 @default.
• W4221031853 hasOpenAccess W4221031853 @default.
• W4221031853 hasPrimaryLocation W42210318531 @default.

• next